Oct 13, 2022. CDIB dedicated to building biomedical ecosystem, with investment in Puriblood, Pregetic to capture China's precision medicine market. To push the biomedical industry into the international arena in the post-pandemic era, CDIB Capital Healthcare Ventures II is dedicated to building a... learn more. Our Mission and Goals.

With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity market. Our Leadership Team. ... President, CDIB Capital Healthcare Ventures. Robert Liu Robert Liu. Managing Director, CDIB YIDA Healthcare Fund. Yen Lu Yen Lu. President, CDIB Yida Private Equity (Kunshan) Co. Ltd.

We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. We seek to seize premium returns in Greater China’s mid-market buyout segment, leveraging on the broader CDF platform and its unique Taiwan heritage in control ...

Chair, Regional Healthcare Practice Chairman, CDIB Capital Healthcare Ventures Head, CDIB Capital Healthcare Ventures II L.P. Achievements. Mr. Ho has almost 30 years of experience in industrial policy, VC investment and executive management. Serving as Deputy Executive Secretary of the Executive Yuan’s Development Fund (later renamed the ...

President of CDIB Capital Healthcare Ventures & CDIB Capital Healthcare Ventures II. Acting president participating in fund establishments since 2012, in charge of planning, constructing and managing fund portfolios. Director/ supervisor at Taiwanese firms TWi, CCSB, Sharehope, Synermore, Axiomtek, and RT-Mart before.

Venture capital and private equity investments in life sciences and healthcare in the Asia-Pacific region (Johnson & Johnson Development Corporation (JJDC)) 2013-19. Joined CDIB in 2019. Expertise in M&A and Investment Transactions

About Us. Meet Our Team. Career. Press. Special Situations. We pursue opportunistic investments that achieve attractive risk-adjusted returns, primarily in North America and Asia Pacific. We also invest across the capital structure in control and non-control situations, and are industry-agnostic.

Venture. We invest in start-up companies with differentiated core strengths, high-growth prospects, asset-light business models, and huge market potential. ... Growth Capital. We invest in companies with strong growth potential and competitive advantage to grow via IPO or M&A strategies.

IPO Assistance. We assist local companies in conducting IPOs in Taiwan, or assist Taiwanese companies in listing on China’s A-share market. We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors.

After joining CDF, Mr. Chang helped raise several private equity/ venture capital funds, including RMB CDIB Private Equity (Fujian) Fund, RMB CDIB Yida Private Equity (Kunshan) Fund, and NTD CDIB Capital Healthcare Venture II, and assisted in CDF’s acquisition of KGI Securities in 2012, Cosmos Bank in 2014 and a 25% stake in China Life in 2017.